Roberto Berni Canani | Molecular Medicine | Best Researcher Award

Posted on by Molecular Biologist

Prof. Roberto Berni Canani | Molecular Medicine | Best Researcher Award 

Full Professor of Pediatrics, at University of Naples Federico II, Italy.

Prof. Dr. Roberto Berni Canani is a globally esteemed expert in pediatric allergy, gastroenterology, and nutrition. He holds the position of Full Professor of Pediatrics at the University of Naples “Federico II” and leads multiple pivotal programs, including the Pediatric Allergy Gastroenterology and Nutrition Program, ImmunoNutritionLab at CEINGE Advanced Biotechnologies, and NutriTechLab. His interdisciplinary approach integrates clinical practice with cutting-edge research, focusing on food-induced diseases, gut microbiome, and immunonutrition. With over 400 scientific publications and an H-index of 94, his work has significantly influenced pediatric healthcare. Prof. Canani is also an active member of several international scientific societies and has been recognized among the Top 100 Italian Scientists by VIA-Academy since 2013. Biocodex Microbiota Institute

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education

Prof. Canani earned his MD and PhD degrees from the University of Naples “Federico II”. His doctoral research delved into the pathophysiology of acute and chronic intestinal diseases, laying the foundation for his future endeavors in pediatric gastroenterology and nutrition. He further specialized in Pediatrics, obtaining board certification, and pursued advanced training through research fellowships and visiting professorships at esteemed institutions such as Harvard Medical School, University of Chicago, and Cincinnati Children’s Hospital. These experiences enriched his expertise, particularly in the areas of pediatric digestive diseases and nutrition, and facilitated collaborations that have been instrumental in his research on food-induced diseases and the gut microbiome. ResearchGate

💼 Experience

With a career spanning over three decades, Prof. Canani has been at the forefront of pediatric healthcare and research. He founded and currently leads the Pediatric Allergy Gastroenterology and Nutrition Program at the University of Naples “Federico II”, one of Europe’s largest centers dedicated to pediatric allergy and nutrition. Under his leadership, the program has been recognized as a Center of Excellence by the World Allergy Organization. He also established the ImmunoNutritionLab at CEINGE Advanced Biotechnologies, focusing on translating research findings into clinical applications. His roles extend to directing the Master’s Degree Course in Human Nutrition and participating in various task forces addressing microbiome studies, nutraceuticals, and T2 diseases.

🔬 Research Interests

Prof. Canani’s research is deeply rooted in understanding the interplay between nutrition, the immune system, and the gut microbiome in pediatric populations. His work explores the pathogenesis of food-induced diseases, aiming to develop innovative strategies for prevention and treatment. Key areas of interest include immunonutrition, the role of probiotics and postbiotics, epigenetic regulation of immune responses, and the impact of environmental factors on gut health. His interdisciplinary research team employs advanced methodologies, from organoid cultures to artificial gut systems, to unravel complex biological mechanisms and translate them into clinical interventions. ceinge.unina.it

🏆 Awards

Prof. Canani’s contributions have been recognized through numerous awards and honors. He has received several scientific prizes for his research activities and has been a member of the Expert Panel and the Dietetic Products, Nutrition, and Allergies Panel of the European Food Safety Authority (EFSA). Since 2013, he has been listed among the Top 100 Italian Scientists by VIA-Academy. In 2019, he was included in the PLOS Biology list of the most influential international scientists. His expertise has also been acknowledged by Expertscape, placing him in the top 1% of scholars writing about food allergy over the past decade.

📚 Top Noted Publications

Prof. Canani has authored over 400 scientific publications, contributing significantly to the fields of pediatric allergy, gastroenterology, and nutrition. His work is widely cited, with more than 44,000 citations and an H-index of 94. Below are some of his notable publications:

1. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants

  • Journal: ISME Journal, 2016; 10(3):742–750

  • Citations: 200+

  • Key Insight: Supplementation with L. rhamnosus GG (LGG) increases butyrate-producing strains, indicating a protective microbiota profile in allergic infants.

2. Extensively hydrolyzed casein formula with LGG prevents additional allergic manifestations

  • Journal: Journal of Allergy and Clinical Immunology, 2017; 139(6):1906–1913.e4

  • Citations: 150+

  • Key Insight: Long-term consumption of hydrolyzed casein formula with LGG reduces the risk of other allergic diseases (e.g., eczema, asthma).

3. Altered miR-193a-5p expression in children with cow’s milk allergy

  • Journal: Allergy, 2018; 73(2):379–386

  • Citations: 100+

  • Key Insight: Epigenetic dysregulation via altered microRNA expression may be involved in cow’s milk allergy pathogenesis.

4. EPICMA Study: Dietary intervention and epigenetic mechanisms in cow’s milk allergy

  • Journal: Scientific Reports, 2019; 9(1):2828

  • Citations: 80+

  • Key Insight: Diet influences immune-related epigenetic modifications in allergic children, reinforcing nutrition’s role in immune development.

5. Healthy infants harbor intestinal bacteria that protect against food allergy

  • Journal: Nature Medicine, 2019; 25(3):448–453

  • Citations: 300+

  • Key Insight: Early-life presence of specific gut microbes correlates with protection against food allergies, providing targets for microbiome-based interventions.

6. Targeting Food Allergy with Probiotics

  • Book Chapter: Advances in Experimental Medicine and Biology, 2019

  • Citations: 50+

  • Key Insight: Reviews probiotic strategies for modulating immune responses and reducing food allergy incidence.

7. Synbiotic trial: L. paracasei B21060 + prebiotics in children with acute diarrhea

  • Journal: Alimentary Pharmacology and Therapeutics, 2012

  • Citations: 70+

  • Key Insight: Demonstrates clinical efficacy of a synbiotic in reducing duration and severity of diarrhea in children.

8. Epigenetic Regulation of Early Nutrition on Immune System

  • Book Chapter: Handbook of Nutrition, Diet, and Epigenetics, 2017

  • Citations: 60+

  • Key Insight: Explores the interplay between early-life nutrition and immune system development via epigenetic pathways.

9. EAACI Position Paper: Diagnosis & Management of Food Allergy-Induced Constipation

  • Journal: Pediatric Allergy and Immunology, 2024; 35(6)

  • Citations: 30+

  • Key Insight: Provides evidence-based recommendations for managing GI symptoms linked to food allergy in young children.

10. Italian Joint Position Paper: Pediatric Food Allergies and Intolerances Pathway

  • Journal: Italian Journal of Pediatrics, 2022

  • Citations: 40+

  • Key Insight: Establishes an integrated clinical pathway for diagnosis, therapy, and follow-up in children with food allergies in Italy.

Conclusion

Prof. Dr. Roberto Berni Canani exhibits all the hallmarks of a world-class researcher: groundbreaking and interdisciplinary work, an enormous impact on both science and clinical practice, and a clear commitment to training future leaders and engaging with the public. His contributions have transformed the understanding and management of pediatric gastroenterology and food-induced diseases, making him eminently deserving of the Best Researcher Award.

Constantin-Ioan Busuioc | Molecular Pathology | Best Researcher Award

Posted on by Molecular Biologist

Dr. Constantin-Ioan Busuioc | Molecular Pathology | Best Researcher Award

Pathologist, at Saint Mary Clinical Hospital, Romania.

Dr. Constantin-Ioan Busuioc is a distinguished Romanian pathologist with a strong background in both clinical and research domains. Born on January 29, 1985, he has devoted his career to exploring the intricate dynamics of pathology, with special focus on oncologic and hematologic conditions. He is currently affiliated with Saint Mary Clinical Hospital in Bucharest, where he plays a pivotal role in surgical specimen analysis and histopathological diagnostics. Over the years, Dr. Busuioc has amassed considerable experience across institutions in Romania, Switzerland, and Italy, enriching his expertise in diagnostic pathology. His research contributions, particularly in colorectal cancer and immunohistochemistry, have gained recognition in high-impact journals. Known for his clinical precision and academic depth, he bridges the gap between research and real-world pathology. Dr. Busuioc is fluent in English and French, and actively participates in both national and international medical networks. 🧬💉🧪

Professional Profile

Scopus

🎓 Education

Dr. Constantin-Ioan Busuioc’s educational journey exemplifies dedication to academic excellence in medicine. He completed his Medical Doctor (M.D.) degree at the University of Medicine and Pharmacy “Iuliu Haţieganu” in Cluj-Napoca, Romania (2005–2011) 🩺. Subsequently, he pursued a Ph.D. at the same institution from 2015 to 2022, delving into molecular and immunohistochemical aspects of malignancies, particularly colorectal adenocarcinoma. His rigorous research training culminated in several significant publications and conference presentations. In 2021, he obtained a Certificate in Health Services Management from the National School of Public Health, Management and Training, enhancing his administrative and healthcare policy knowledge 📊. Additionally, he undertook a fellowship in Hematopathology at the prestigious European Institute of Oncology in Milan, Italy, under Prof. Dr. Stefano A. Pileri. This diverse academic path has equipped him with a well-rounded perspective, blending clinical pathology, biomedical research, and health systems management. 📚🧠

🏥 Experience

With over a decade of professional experience, Dr. Busuioc has held key pathology roles across several European institutions. His current role at Saint Mary Clinical Hospital (since 2023) involves high-stakes diagnostics, intraoperative evaluations, and necropsies. From 2021 to 2023, he served at the National Institute of Infectious Diseases “Prof. Dr. Matei Balș”, specializing in infectious pathology, autopsies, and immunohistochemistry. 🧫 Earlier roles include long-term service at Oncoteam Diagnostic and previous tenure at Synevo, where he managed complex diagnostic cases involving general and hematopathology. Internationally, he worked as Chef de Clinique at Valais Hospital in Switzerland (2018–2019) and completed an intensive fellowship at the European Institute of Oncology, Italy. His foundational years were spent as a resident at Cluj-Napoca County Hospital, with rotations at specialized hospitals including the Oncology Institute and Gastroenterology Institute. His vast experience shapes his precision in diagnosis and depth in pathology. 🧬🦠

🧠 Research Interests

Dr. Busuioc’s research interests lie at the intersection of molecular oncology, immunohistochemistry, and epithelial-mesenchymal transition (EMT) in gastrointestinal malignancies, particularly colorectal and esophageal cancers. He is also intrigued by gene expression profiling, diagnostic biomarkers, and tumor microenvironment interactions. 🧬 His studies often explore the role of EMT markers like Vimentin and E-cadherin in predicting tumor progression. Utilizing bioinformatics tools, he analyzes molecular pathways and gene signatures such as MMP3 and TESC, aiming to enhance early detection and personalized treatment approaches. He has contributed significantly to the understanding of PD-L1 expression, particularly in esophageal carcinoma, and its immunological implications. Additionally, he has co-authored studies on rare case presentations such as Kikuchi-Fujimoto disease and lymphomas in gynecological tissues. His collaborative approach and interdisciplinary mindset make his research impactful and translational. 🔍🧫

🏆 Awards

Dr. Constantin-Ioan Busuioc has earned recognition for his commitment to excellence in pathology and oncology research. One of the highlights of his academic career is being part of the UEFISCDI-awarded article published in Cancers (Basel), which offered a comprehensive review of MAPK pathways as therapeutic targets in cancer. 🏅 His insightful contributions to colorectal cancer pathology and bioinformatics analysis have garnered attention in Romanian medical circles and abroad. His consistent publication in high-impact journals reflects a commendable academic rigor. He has also been nominated for multiple academic awards through Romanian and European research forums. His interdisciplinary case studies, particularly in complex co-morbidities, showcase his versatility as both a clinician and a researcher. These recognitions not only validate his scientific acumen but also reinforce his status as a dedicated and innovative medical professional. 🌟📖

📚Top Noted Publications

Dr. Busuioc has co-authored 12+ peer-reviewed articles in reputable international journals, reflecting his impactful work in pathology and molecular oncology:

  1. Aberrant Immunohistochemical Expression in Colorectal Adenocarcinoma
    Chirurgia (Bucur), 2022

    • Focus: Aberrant IHC patterns in colorectal cancer

    • Citations: 5

    • Notes: Highlights novel expression markers potentially linked to prognosis and therapy responsiveness.

  2. MMP3 & TESC in Colon Adenocarcinoma
    BioMedInformatics, 2022

    • Focus: Role of MMP3 and TESC genes in colon cancer progression using computational biology tools

    • Citations: 2

  3. EMT Gene Signature & Prognosis in Colon Adenocarcinoma
    Journal of Personalized Medicine, 2021

    • Focus: EMT-related gene expression linked to prognosis and patient stratification

    • Citations: 10

    • Impact: Widely referenced in personalized therapy literature.

  4. PD-L1 Expression in Esophageal Carcinomas
    Chirurgia (Bucur), 2022

    • Focus: PD-L1 immunostaining in esophageal cancer subtypes

    • Notes: Adds data to the ongoing debate on immunotherapy eligibility.

  5. MAPK Pathways Review: Biological Mechanisms & Therapeutic Targets in Oncology
    Cancers (Basel), 2019

    • Focus: Comprehensive review of MAPK signaling in cancer

    • Citations: 100+

    • Recognition: Award-winning article, highly cited in targeted therapy discussions.

  6. Multidisciplinary Team in Rectal Cancer Management: Integration & Outcomes
    Clujul Med, 2017

    • Focus: Clinical coordination in colorectal cancer treatment

    • Notes: Addresses practical framework for collaborative cancer care.

🩺 Internal Medicine, Autoimmunity & Rare Conditions

  1. Case of Acute Polyarthritis with Severe Comorbidity
    Internal Medicine, 2021

    • Focus: Complex internal medicine case with overlapping rheumatological and systemic features

  2. Sarcoidosis Associated with Solid Pseudopapillary Tumor: A Diagnostic Rarity
    Romanian Journal of Internal Medicine, 2022

    • Focus: Uncommon tumor presentation in a patient with sarcoidosis

  3. Episcleritis in Granulomatosis with Polyangiitis: A Diagnostic Challenge
    Romanian Journal of Ophthalmology, 2021

    • Focus: Ocular manifestation of a systemic vasculitis

  4. Kikuchi-Fujimoto Disease Mimicking Systemic Lupus Erythematosus
    Romanian Journal of Rhinology, 2022

    • Focus: Autoimmune overlap and diagnostic pitfalls

  5. Primary Gynecological Lymphomas: A Behavioural Case Perspective
    Annals of Behavioural Science, 2018

    • Focus: Behavioral and clinical aspects of gynecological lymphoma diagnosis and management

Conclusion

Dr. Constantin-Ioan Busuioc is a strong candidate for a Best Researcher Award, especially in the field of oncopathology, molecular diagnostics, and histopathology. His blend of clinical practice, interdisciplinary research, and international experience makes him highly competitive. With enhanced visibility in research leadership roles and international scholarly forums, his profile would be further elevated to a global best researcher standard.

Camille EVRARD | Molecular Biology | Best Researcher Award

Posted on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.